Biogen bolsters gene therapy portfolio

Biogen Inc. (NASDAQ:BIIB) and the University of Pennsylvania will collaborate to develop gene therapies for eye, skeletal muscle and CNS conditions.

Biogen will pay $20 million up front to UPenn,

Read the full 304 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE